For the pharmaceutical industry, the last few years have been nothing short of ideal. Drug labs have been churning out a string of fast-selling products. With speedier approval of new drugs at the Food & Drug Administration, Washington was largely a benign force. And while managed-care companies grumbled about the rising cost of prescription drugs, they seemed unable to do anything to stop consumers from enthusiastically adopting expensive new therapies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.